Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 1 to 10 of 69

Keyword or reference number: cancerRemove Keyword or reference number: cancer filter

Guidance and quality standards awaiting development
Title	Type
Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate cancer [ID6471]	Technology appraisal guidance
Artificial Intelligence in MRI for prostate cancer diagnosis	Health technology evaluation
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID3894]	Technology appraisal guidance
Atezolizumab for adjuvant treatment of circulating tumour DNA-positive high-risk muscle-invasive bladder cancer after cystectomy [ID6515]	Technology appraisal guidance
Atezolizumab with BCG before surgery (neoadjuvant) for treating non-muscle-invasive bladder cancer [ID6667]	Technology appraisal guidance
Atezolizumab with chemotherapy for adjuvant treatment of stage 3 colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID6646]	Technology appraisal guidance
Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer [TSID11769]	Technology appraisal guidance
Bevacizumab (Avastin and biosimilars) with fluoropyrimidine-based chemotherapy for untreated metastatic colorectal cancer [ID6465]	Technology appraisal guidance
Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387]	Technology appraisal guidance
Camizestrant with palbociclib for untreated oestrogen receptor-positive HER2-negative metastatic breast cancer after adjuvant endocrine treatment [ID6534]	Technology appraisal guidance

Results per page

10
25
50
All